Franco Locatelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6212489/publications.pdf

Version: 2024-02-01

366 papers 19,602 citations

70 h-index 123 g-index

371 all docs

371 docs citations

371 times ranked

19061 citing authors

#	Article	IF	CITATIONS
1	CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \hat{l}^2 -Thalassemia. New England Journal of Medicine, 2021, 384, 252-260.	27.0	939
2	Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 2010, 115, 3206-3214.	1.4	685
3	Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 4381-4389.	1.6	478
4	HLA-haploidentical stem cell transplantation after removal of $\hat{l}\pm\hat{l}^2+$ T and B cells in children with nonmalignant disorders. Blood, 2014, 124, 822-826.	1.4	385
5	Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 2011, 118, 2077-2084.	1.4	370
6	Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood, 2009, 113, 3119-3129.	1.4	343
7	Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. New England Journal of Medicine, 2020, 382, 1811-1822.	27.0	320
8	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nature Genetics, 2010, 42, 794-800.	21.4	308
9	Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood, 2016, 127, 1387-1397.	1.4	304
10	Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood, 2005, 105, 410-419.	1.4	291
11	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 2949-2962.	1.6	277
12	Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Frontiers in Immunology, 2019, 10, 1179.	4.8	269
13	How I treat relapsed childhood acute lymphoblastic leukemia. Blood, 2012, 120, 2807-2816.	1.4	263
14	Outcome of children with acute leukemia given HLA-haploidentical HSCT after $\hat{l}\pm\hat{l}^2$ T-cell and B-cell depletion. Blood, 2017, 130, 677-685.	1.4	261
15	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood, 2009, 114, 1859-1863.	1.4	260
16	Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood, 2014, 123, 133-140.	1.4	239
17	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. Journal of Allergy and Clinical Immunology, 2018, 141, 1036-1049.e5.	2.9	233
18	$\hat{I}^3\hat{I}$ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR- $\hat{I}\pm\hat{I}^2+$ /CD19+ lymphocytes. Blood, 2015, 125, 2349-2358.	1.4	224

#	Article	IF	CITATIONS
19	Inhibition of Natural Killer Cell Cytotoxicity by Interleukinâ€6: Implications for the Pathogenesis of Macrophage Activation Syndrome. Arthritis and Rheumatology, 2015, 67, 3037-3046.	5.6	222
20	Killer Ig \hat{a} e"like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood, 2011, 117, 764-771.	1.4	218
21	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. New England Journal of Medicine, 2021, 385, 228-238.	27.0	209
22	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood, 2016, 127, 2101-2112.	1.4	208
23	Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2005, 129, 622-630.	2.5	206
24	Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood, 2002, 100, 1192-1200.	1.4	201
25	GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood, 2005, 106, 447-453.	1.4	196
26	How I treat juvenile myelomonocytic leukemia. Blood, 2015, 125, 1083-1090.	1.4	189
27	Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. Journal of Clinical Oncology, 2019, 37, 2246-2256.	1.6	186
28	Human Cytomegalovirus Infection Promotes Rapid Maturation of NK Cells Expressing Activating Killer Ig–like Receptor in Patients Transplanted with NKG2Câ~'/â~' Umbilical Cord Blood. Journal of Immunology, 2014, 192, 1471-1479.	0.8	176
29	Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2001, 19, 3675-3684.	1.6	173
30	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 843.	7.4	166
31	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. Journal of Clinical Oncology, 2021, 39, 295-307.	1.6	163
32	Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, 2013, 122, 170-178.	1.4	162
33	Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood, 2003, 102, 4290-4297.	1.4	160
34	Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood, 2000, 95, 1572-1579.	1.4	153
35	Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nature Genetics, 2017, 49, 451-456.	21.4	152
36	Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases. Frontiers in Immunology, 2020, 11, 610300.	4.8	149

#	Article	IF	Citations
37	Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood, 2001, 97, 3995-3997.	1.4	147
38	Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry. Journal of Allergy and Clinical Immunology, 2016, 137, 188-196.e4.	2.9	139
39	Results of Unrelated Cord Blood Transplant in Fanconi Anemia Patients: Risk Factor Analysis for Engraftment and Survival. Biology of Blood and Marrow Transplantation, 2007, 13, 1073-1082.	2.0	138
40	NK cells and ILCs in tumor immunotherapy. Molecular Aspects of Medicine, 2021, 80, 100870.	6.4	134
41	KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood, 2014, 124, 2744-2747.	1.4	132
42	A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. Journal of Experimental Medicine, 2019, 216, 2778-2799.	8.5	132
43	The immune system of children: the key to understanding SARS-CoV-2 susceptibility?. The Lancet Child and Adolescent Health, 2020, 4, 414-416.	5.6	132
44	Extracorporeal photochemotherapy for treatmentof acute and chronic GVHD in childhood. Transfusion, 2001, 41, 1299-1305.	1.6	131
45	Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood, 2007, 109, 4641-4647.	1.4	126
46	Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood, 2006, 107, 2984-2992.	1.4	123
47	Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncolmmunology, 2018, 7, e1433518.	4.6	120
48	CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood, 2013, 121, 3469-3472.	1.4	119
49	NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia. Trends in Immunology, 2018, 39, 577-590.	6.8	119
50	Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. British Journal of Haematology, 2002, 116, 465-467.	2.5	116
51	Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. Journal of Clinical Oncology, 2016, 34, 919-926.	1.6	111
52	Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncolmmunology, 2015, 4, e1019981.	4.6	105
53	Modeling medulloblastoma in vivo and with human cerebellar organoids. Nature Communications, 2020, 11, 583.	12.8	105
54	Unrelated donor vs HLA-haploidentical α/β T-cell– and B-cell–depleted HSCT in children with acute leukemia. Blood, 2018, 132, 2594-2607.	1.4	101

#	Article	IF	CITATIONS
55	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	21.4	97
56	Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death and Disease, 2020, 11, 921.	6.3	96
57	Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematology,the, 2016, 3, e80-e86.	4.6	95
58	Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood, 2011, 117, 4871-4880.	1.4	94
59	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 12-24.	2.4	94
60	RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nature Communications, 2017, 8, 2126.	12.8	91
61	Betibeglogene Autotemcel Gene Therapy for Non–β ⁰ /β ⁰ Genotype β-Thalassemia. New England Journal of Medicine, 2022, 386, 415-427.	27.0	91
62	Negative depletion of $\hat{l}\pm/\hat{l}^2+T$ cells and of CD19+ B lymphocytes: A novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunology Letters, 2013, 155, 21-23.	2.5	90
63	Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. Nature Communications, 2020, 11, 5992.	12.8	87
64	Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4+ and CD4â ⁻² Subset Dynamics and Correlates with Remission State. Journal of Immunology, 2011, 186, 4490-4499.	0.8	85
65	Natural killer cells in the treatment of high-risk acute leukaemia. Seminars in Immunology, 2014, 26, 173-179.	5.6	85
66	A novel self-lipid antigen targets human T cells against CD1c+ leukemias. Journal of Experimental Medicine, 2014, 211, 1363-1377.	8.5	80
67	Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing $\hat{A}\hat{A}$ +T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies. Haematologica, 2016, 101, 371-381.	3.5	80
68	Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood, 2013, 122, 2135-2141.	1.4	79
69	Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. Blood, 2016, 127, 3424-3430.	1.4	79
70	Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematology,the, 2018, 5, e450-e461.	4.6	79
71	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nature Medicine, 2021, 27, 1806-1817.	30.7	79
72	Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors. Frontiers in Immunology, 2014, 5, 87.	4.8	77

#	Article	IF	CITATIONS
73	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica, 2014, 99, 865-872.	3.5	77
74	Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference. Clinical Immunology, 2009, 133, 171-178.	3.2	76
75	The Interplay between CD27dull and CD27bright B Cells Ensures the Flexibility, Stability, and Resilience of Human B Cell Memory. Cell Reports, 2020, 30, 2963-2977.e6.	6.4	76
76	Autoimmune Hematological Diseases after Allogeneic Hematopoietic Stem Cell Transplantation in Children: An Italian Multicenter Experience. Biology of Blood and Marrow Transplantation, 2014, 20, 272-278.	2.0	75
77	Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. Cell Host and Microbe, 2022, 30, 400-408.e4.	11.0	75
78	Gene Expression–Based Classification As an Independent Predictor of Clinical Outcome in Juvenile Myelomonocytic Leukemia. Journal of Clinical Oncology, 2010, 28, 1919-1927.	1.6	74
79	Multifunctional human CD56low CD16low natural killer cells are the prominent subset in bone marrow of both healthy pediatric donors and leukemic patients. Haematologica, 2015, 100, 489-498.	3.5	72
80	Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). Journal of Clinical Oncology, 2018, 36, 244-253.	1.6	71
81	Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Pharmacotherapy, 2014, 15, 23-36.	1.8	69
82	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood, 2015, 126, 1575-1584.	1.4	69
83	Treosulfanâ€based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. British Journal of Haematology, 2015, 169, 726-736.	2.5	68
84	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer Journal, 2020, 10, 77.	6.2	65
85	Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1970-1985.e4.	3.8	64
86	Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica, 2008, 93, 1694-1701.	3.5	62
87	\hat{l}^2 -arrestin 1 -mediated acetylation of Gli 1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells. BMC Cancer, 2017, 17, 488.	2.6	62
88	Highly Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA. Cells, 2021, 10, 2541.	4.1	61
89	Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood, 2008, 111, 966-967.	1.4	60
90	Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood, 2015, 125, 2311-2313.	1.4	60

#	Article	IF	CITATIONS
91	Selective Depletion of αβ T Cells and B Cells for Human Leukocyte Antigen–Haploidentical Hematopoietic Stem Cell Transplantation. A Three-Year Follow-Up of Procedure Efficiency. Biology of Blood and Marrow Transplantation, 2016, 22, 2056-2064.	2.0	59
92	Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 1126-1136.	10.7	58
93	Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica, 2014, 99, 1248-1254.	3.5	57
94	At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies. Journal of Leukocyte Biology, 2013, 94, 1141-1157.	3.3	56
95	Prognostic significance of flowâ€cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the ⟨scp⟩AIEOP⟨ scp⟩â€⟨scp⟩AML⟨ scp⟩ 2002 01 study protocol. British Journal of Haematology, 2017, 177, 116-126.	2.5	54
96	NK Cell-Based Immunotherapy for Hematological Malignancies. Journal of Clinical Medicine, 2019, 8, 1702.	2.4	54
97	HLA-Haploidentical T Cell–Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Children with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2014, 20, 571-576.	2.0	52
98	ERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors. Cancer Research, 2015, 75, 824-834.	0.9	52
99	Human innate lymphoid cells. Immunology Letters, 2016, 179, 2-8.	2.5	52
100	Role of interferon- \hat{i}^3 in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation. Haematologica, 2019, 104, 2314-2323.	3.5	52
101	Durable remissions in <i>TCF3-HLF</i> positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica, 2019, 104, e244-e247.	3.5	52
102	Thymic function recovery after unrelated donor cord blood or T-cell depleted HLA-haploidentical stem cell transplantation correlates with leukemia relapse. Frontiers in Immunology, 2013, 4, 54.	4.8	51
103	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica, 2020, 105, 47-58.	3.5	51
104	Robot-Assisted Stereotactic Biopsy of Diffuse Intrinsic Pontine Glioma: A Single-Center Experience. World Neurosurgery, 2017, 101, 584-588.	1.3	50
105	A literature review of 2019 novel coronavirus (SARS-CoV2) infection in neonates and children. Pediatric Research, 2021, 89, 1101-1108.	2.3	48
106	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood, 2021, 137, 1582-1590.	1.4	48
107	Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. Haematologica, 2019, 104, e543-e546.	3.5	47
108	Compound heterozygosity for two different amino-acid substitution mutations in the thrombopoietin receptor (c-mpl gene) in congenital amegakaryocytic thrombocytopenia (CAMT). Human Genetics, 2000, 107, 225-233.	3.8	46

#	Article	IF	Citations
109	Germâ€line mutation of the <i>NRAS</i> gene may be responsible for the development of juvenile myelomonocytic leukaemia. British Journal of Haematology, 2009, 147, 706-709.	2.5	46
110	Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood, 2018, 132, 405-412.	1.4	46
111	No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood, 2011, 118, 6683-6690.	1.4	45
112	Acute Myeloid Leukemia in Infants: Biology and Treatment. Frontiers in Pediatrics, 2015, 3, 37.	1.9	45
113	NK Cells and Other Innate Lymphoid Cells in Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2016, 7, 188.	4.8	45
114	Prognostic impact of $t(16;21)(p11;q22)$ and $t(16;21)(q24;q22)$ in pediatric AML: a retrospective study by the I-BFM Study Group. Blood, 2018, 132, 1584-1592.	1.4	45
115	Total Body Irradiation, Thiotepa, and Cyclophosphamide as a Conditioning Regimen for Children With Acute Lymphoblastic Leukemia in First or Second Remission Undergoing Bone Marrow Transplantation With HLA-Identical Siblings. Journal of Clinical Oncology, 1999, 17, 1838-1838.	1.6	44
116	Pre―and postâ€ŧransplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 180, 680-693.	2.5	44
117	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica, 2015, 100, 17-22.	3.5	43
118	CBFA2T3â€GLIS2â€positive acute myeloid leukaemia. A peculiar paediatric entity. British Journal of Haematology, 2019, 184, 337-347.	2.5	43
119	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies. International Journal of Infectious Diseases, 2020, 96, 431-439.	3.3	43
120	Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, 1786-1791.	2.0	42
121	Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies. Frontiers in Immunology, 2019, 10, 316.	4.8	42
122	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?â€"A multicenter EBMT-PDWP study. Bone Marrow Transplantation, 2020, 55, 1540-1551.	2.4	42
123	Incidence of, and Risk Factors for, Nosocomial Infections Among Hematopoietic Stem Cell Transplantation Recipients, With Impact on Procedure-Related Mortality. Infection Control and Hospital Epidemiology, 2001, 22, 510-517.	1.8	41
124	Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 467-474.	2.0	41
125	Clinical Implications of Minimal Residual Disease Detection in Infants With <i>KMT2A</i> Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Journal of Clinical Oncology, 2021, 39, 652-662.	1.6	41
126	Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective. Trends in Molecular Medicine, 2017, 23, 1156-1175.	6.7	40

#	Article	IF	CITATIONS
127	Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy. Biology of Blood and Marrow Transplantation, 2018, 24, 1223-1231.	2.0	39
128	Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)- $\hat{l}\pm\hat{l}^2$ /CD19-depleted haploidentical stem cell grafts. Journal of Translational Medicine, 2014, 12, 240.	4.4	38
129	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. Haematologica, 2015, 100, 315-323.	3.5	38
130	Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia. Cancer Discovery, 2019, 9, 1736-1753.	9.4	37
131	Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. Haematologica, 2015, 100, e99-e101.	3.5	35
132	Human NK cells: From surface receptors to clinical applications. Immunology Letters, 2016, 178, 15-19.	2.5	35
133	B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies. Cells, 2021, 10, 2915.	4.1	35
134	Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in <i>BRAF</i> V600–mutant pediatric low-grade glioma (pLGC) Journal of Clinical Oncology, 2022, 40, LBA2002-LBA2002.	1.6	35
135	<i>RASA4</i> undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics, 2014, 9, 1252-1260.	2.7	34
136	Longâ€term results of highâ€dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. British Journal of Haematology, 2015, 170, 398-407.	2.5	34
137	Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. Journal of Hematology and Oncology, 2017, 10, 26.	17.0	34
138	AMBRA1 Controls Regulatory T-Cell Differentiation and Homeostasis Upstream of the FOXO3-FOXP3 Axis. Developmental Cell, 2018, 47, 592-607.e6.	7.0	34
139	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood, 2008, 111, 1124-1127.	1.4	33
140	The Cannabinoid Receptor Type 2 as Mediator of Mesenchymal Stromal Cell Immunosuppressive Properties. PLoS ONE, 2013, 8, e80022.	2.5	33
141	MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. Oncolmmunology, 2017, 6, e1316439.	4.6	33
142	High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric <scp>HSCT</scp> : a prospective multicentre study. British Journal of Haematology, 2017, 179, 772-780.	2.5	33
143	Hematopoietic Stem Cell Transplantation in Thalassemia. Hematology/Oncology Clinics of North America, 2018, 32, 317-328.	2.2	33
144	Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica, 2020, 105, 1887-1894.	3.5	33

#	Article	IF	Citations
145	Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma. Nature Communications, 2021, 12, 192.	12.8	33
146	Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn ErrorsÂWorking Party analysis. Blood, 2022, 139, 2066-2079.	1.4	33
147	ACUTE PROMYELOCYTIC LEUKEMIA (APL): COMPARISON BETWEEN CHILDREN AND ADULTS. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014032.	1.3	32
148	Stimuli-responsive nanoparticle-assisted immunotherapy: a new weapon against solid tumours. Journal of Materials Chemistry B, 2020, 8, 1823-1840.	5.8	32
149	Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells. Frontiers in Immunology, 2019, 10, 2717.	4.8	31
150	Use of critical care resources during the first 2 weeks (February 24–March 8, 2020) of the Covid-19 outbreak in Italy. Annals of Intensive Care, 2020, 10, 133.	4.6	31
151	Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro-Oncology, 2022, 24, 1150-1163.	1.2	31
152	Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. Haematologica, 2013, 98, 1273-1281.	3.5	30
153	Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition. Cancers, 2020, 12, 2684.	3.7	30
154	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <scp>EBMT</scp> group. American Journal of Hematology, 2020, 95, 809-816.	4.1	30
155	Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL) Tj ETQq1	l 0.7184431	4 rgBō/Overlo
156	MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. Oncotarget, 2016, 7, 55395-55408.	1.8	30
157	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Annals of Hematology, 2020, 99, 2215-2229.	1.8	29
158	The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. Haematologica, 2021, 106, 630-634.	3.5	29
159	Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Advances, 2021, 5, 2901-2908.	5.2	29
160	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. Journal of the National Cancer Institute, 2022, 114, 436-445.	6.3	29
161	Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. Biomarker Research, 2015, 3, 13.	6.8	28
162	Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immunoevasion. Cell Reports, 2017, 20, 846-853.	6.4	28

#	Article	IF	CITATIONS
163	Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood, 2022, 139, 1785-1793.	1.4	28
164	Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. Bone Marrow Transplantation, 2020, 55, 1918-1927.	2.4	28
165	Kaposi's Sarcoma in a child after autologous bone marrow transplantation for non-Hodgkin's lymphoma. Cancer, 1991, 68, 1361-1364.	4.1	27
166	Farber disease in infancy resembling juvenile idiopathic arthritis: identification of two new mutations and a good early response to allogeneic haematopoietic stem cell transplantation. Rheumatology, 2014, 53, 1533-1534.	1.9	27
167	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia, 2022, 36, 1525-1532.	7.2	27
168	Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children. Haematologica, 2014, 99, e127-e129.	3.5	26
169	Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia, 2020, 34, 2473-2478.	7.2	26
170	Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course. Blood, 2021, 138, 557-570.	1.4	26
171	The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency. Frontiers in Immunology, 2021, 12, 815404.	4.8	26
172	Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study. Bone Marrow Transplantation, 2019, 54, 1632-1642.	2.4	25
173	Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants., 2021, 9, e002293.		25
174	Improving cord blood transplantation in children. British Journal of Haematology, 2009, 147, 217-226.	2.5	24
175	Iron overload enhances human mesenchymal stromal cell growth and hampers matrix calcification. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1211-1223.	2.4	24
176	Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. Bone Marrow Transplantation, 2021, 56, 2732-2741.	2.4	24
177	<i>CRLF2</i> over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 59260-59272.	1.8	24
178	Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. European Journal of Cancer, 2022, 164, 1-17.	2.8	24
179	DHH-RHEBL1fusion transcript: a novel recurrent feature in the new landscape of pediatricCBFA2T3-GLIS2-positive acute myeloid leukemia. Oncotarget, 2013, 4, 1712-1720.	1.8	23
180	Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation. Expert Review of Clinical Immunology, 2016, 12, 343-358.	3.0	22

#	Article	IF	CITATIONS
181	Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. Biology of Blood and Marrow Transplantation, 2018, 24, 799-805.	2.0	22
182	Delayed referral of pediatric brain tumors during COVID-19 pandemic. Neuro-Oncology, 2020, 22, 1884-1886.	1.2	22
183	Nutlin-3a Enhances Natural Killer Cell–Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors. Cancer Immunology Research, 2021, 9, 170-183.	3.4	22
184	HLA-haploidentical TCR \hat{l} ± \hat{l} 2+/CD19+-depleted stem cell transplantation in children and young adults with Fanconi anemia. Blood Advances, 2021, 5, 1333-1339.	5.2	22
185	Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 424.e1-424.e9.	1.2	22
186	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. Frontiers in Immunology, 2021, 12, 704110.	4.8	22
187	$TCR\hat{l}\pm\hat{l}^2/CD19$ depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders. Blood Advances, 2022, 6, 281-292.	5.2	22
188	Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to â‰25 years with relapsed/refractory osteosarcoma (OS) Journal of Clinical Oncology, 2018, 36, 11527-11527.	1.6	22
189	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Advances, 2022, 6, 1004-1014.	5.2	22
190	Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study. Haematologica, 2004, 89, 1054-61.	3.5	22
191	ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. Haematologica, 2019, 104, 533-545.	3.5	21
192	Immune Modulation Properties of Zoledronic Acid on $TcR^{\hat{1}\hat{3}\hat{1}}$ T-Lymphocytes After $TcR^{\hat{1}\hat{2}}$ CD19-Depleted Haploidentical Stem Cell Transplantation: An analysis on 46 Pediatric Patients Affected by Acute Leukemia. Frontiers in Immunology, 2020, 11, 699.	4.8	21
193	Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention. Progress in Neurobiology, 2021, 196, 101892.	5.7	21
194	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. Blood Cancer Discovery, 2021, 2, 586-599.	5.0	21
195	Mutations of <i>SETBP1</i> and <i>JAK3</i> in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. Oncotarget, 2016, 7, 28914-28919.	1.8	21
196	Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia, 2022, 36, 1516-1524.	7.2	21
197	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
198	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. British Journal of Cancer, 2017, 116, 335-343.	6.4	20

#	Article	IF	CITATIONS
199	Loss of miR-107, miR-181c and miR-29a-3p Promote Activation of Notch2 Signaling in Pediatric High-Grade Gliomas (pHGGs). International Journal of Molecular Sciences, 2017, 18, 2742.	4.1	19
200	Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. Expert Review of Hematology, 2018, 11, 129-143.	2.2	19
201	Phenotypic and Functional Characterization of NK Cells in $\hat{l}\pm\hat{l}^2$ T-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia. Cancers, 2020, 12, 2187.	3.7	19
202	Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML. Cancers, 2020, 12, 1972.	3.7	19
203	Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL). Blood, 2014, 124, 795-795.	1.4	19
204	Outcome of children with acute myeloid leukaemia (<scp>AML</scp>) experiencing primary induction failure in the <scp>AIEOP AML</scp> 2002/01 clinical trial. British Journal of Haematology, 2015, 171, 566-573.	2.5	18
205	Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. Bone Marrow Transplantation, 2020, 55, 1996-2007.	2.4	18
206	Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML. Leukemia, 2018, 32, 1124-1134.	7.2	17
207	Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL). Frontiers in Immunology, 2020, 11, 608492.	4.8	17
208	The role of interferonâ€gamma and its signaling pathway in pediatric hematological disorders. Pediatric Blood and Cancer, 2021, 68, e28900.	1.5	17
209	Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia. Cancer Immunology Research, 2022, 10, 291-302.	3.4	17
210	Eltrombopag for treatment of thrombocytopenia-associated disorders. Expert Opinion on Pharmacotherapy, 2015, 16, 2243-2256.	1.8	16
211	Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. Human Mutation, 2018, 39, 579-587.	2.5	16
212	CB2 Receptor Stimulation and Dexamethasone Restore the Anti-Inflammatory and Immune-Regulatory Properties of Mesenchymal Stromal Cells of Children with Immune Thrombocytopenia. International Journal of Molecular Sciences, 2019, 20, 1049.	4.1	16
213	PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients. Pharmacogenomics Journal, 2020, 20, 415-425.	2.0	15
214	Monocyte–macrophage polarization and recruitment pathways in the tumour microenvironment of Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 1157-1171.	2.5	15
215	Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study. Transplantation and Cellular Therapy, 2022, 28, 99.e1-99.e7.	1.2	15
216	Impaired memory B-cell response to the Pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2022, 149, 76-77.	2.9	15

#	Article	IF	CITATIONS
217	Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study Journal of Clinical Oncology, 2022, 40, 10001-10001.	1.6	15
218	Oligophrenin-1 (OPHN1), a Gene Involved in X-Linked Intellectual Disability, Undergoes RNA Editing and Alternative Splicing during Human Brain Development. PLoS ONE, 2014, 9, e91351.	2.5	14
219	Large cell anaplastic medulloblastoma metastatic to the scalp: tumor and derived stem-like cells features. BMC Cancer, 2014, 14, 262.	2.6	14
220	Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing. Journal of Hematology and Oncology, 2015, 8, 69.	17.0	14
221	Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel. British Journal of Haematology, 2016, 175, 588-601.	2.5	14
222	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. Pediatric Blood and Cancer, 2017, 64, e26664.	1.5	14
223	Arsenic trioxide and allâ€trans retinoic acid treatment for childhood acute promyelocytic leukaemia. British Journal of Haematology, 2019, 185, 360-363.	2.5	14
224	Outcome of adolescent patients with acute lymphoblastic leukaemia aged $10\hat{a}\in 14$ years as compared with those aged $15\hat{a}\in 17$ years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. European Journal of Cancer, 2019, 122, 61-71.	2.8	14
225	The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children. Critical Reviews in Oncology/Hematology, 2019, 138, 132-138.	4.4	14
226	The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment. Seminars in Immunopathology, 2021, 43, 101-117.	6.1	14
227	MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. International Journal of Molecular Sciences, 2021, 22, 10671.	4.1	14
228	Core Binding Factor Acute Myeloid Leukemia In Pediatric Patients Enrolled In The AIEOP AML 2002/01 Trial: The Impact Of Minimal Residual Disease On Patient Outcome. Blood, 2013, 122, 3884-3884.	1.4	14
229	Extracorporeal photopheresis for paediatric patients experiencing graft-versus-host disease (GVHD). Transfusion and Apheresis Science, 2014, 50, 340-348.	1.0	13
230	Haploidentical Haematopoietic Stem Cell Transplantation: Role of NK Cells and Effect of Cytomegalovirus Infections. Current Topics in Microbiology and Immunology, 2015, 395, 209-224.	1.1	13
231	Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. Leukemia, 2020, 34, 3042-3046.	7.2	13
232	Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric modelâ€based approach. British Journal of Clinical Pharmacology, 2022, 88, 2128-2139.	2.4	13
233	Cord blood transplantation in children with haematological malignancies. Best Practice and Research in Clinical Haematology, 2010, 23, 189-196.	1.7	12
234	Consensus of the Italian Primary Immunodeficiency Network on transition management from pediatric to adult care in patients affected with childhood-onset inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2020, 146, 967-983.	2.9	12

#	Article	IF	CITATIONS
235	Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective Iâ€BFM analysis of 333 children. British Journal of Haematology, 2020, 189, 745-750.	2.5	12
236	Recurrent genetic fusions redefine <i>MLL </i> germ line acute lymphoblastic leukemia in infants. Blood, 2021, 137, 1980-1984.	1.4	12
237	Frequency of donor cytotoxic T cell precursors does not correlate with occurrence of acute graft-versus-host disease in children transplanted using unrelated donors. Journal of Clinical Immunology, 1996, 16, 107-114.	3.8	11
238	Treatment of disease recurrence after allogeneic hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia: A great challenge still to be won. Pediatric Blood and Cancer, 2013, 60, 1-2.	1.5	11
239	Targeting BAG-1: A novel strategy to increase drug efficacy in acute myeloid leukemia. Experimental Hematology, 2015, 43, 180-190.e6.	0.4	11
240	Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy. Frontiers in Immunology, 2021, 12, 752042.	4.8	11
241	Quantitative ultrasound detects bone impairment after bone marrow transplantation in children and adolescents affected by hematological diseases. Bone, 2008, 43, 177-182.	2.9	10
242	Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2019, 184, 397-404.	2.5	10
243	NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles. Seminars in Hematology, 2020, 57, 175-184.	3.4	10
244	Cord blood transplantation for acute leukemia. Expert Opinion on Biological Therapy, 2020, 20, 1223-1236.	3.1	10
245	<scp>CD56</scp> , <scp>HLAâ€DR,</scp> and <scp>CD45</scp> recognize a subtype of childhood <scp>AML</scp> harboring <scp>CBFA2T3â€GLIS2</scp> fusion transcript. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 844-850.	1.5	10
246	Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts., 2021, 9, e001514.		10
247	The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia. Journal of Clinical Medicine, 2021, 10, 3790.	2.4	10
248	A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study. Blood, 2020, 136, 8-9.	1.4	10
249	Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm. Blood, 2013, 122, 4378-4378.	1.4	10
250	Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells. British Journal of Haematology, 2022, 197, 110-119.	2.5	10
251	Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric highâ€risk first relapse Bâ€cell precursor acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2022, 69, e29715.	1.5	10
252	Philadelphia-Like Signature In Childhood Acute Lymphoblastic Leukemia: The AIEOP Experience. Blood, 2013, 122, 353-353.	1.4	9

#	Article	IF	CITATIONS
253	Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. Blood Advances, 2021, 5, 262-273.	5.2	9
254	CAPE and its synthetic derivative VP961 restore BACH1/NRF2 axis in Down Syndrome. Free Radical Biology and Medicine, 2022, 183, 1-13.	2.9	9
255	MicroRNAs-Proteomic Networks Characterizing Human Medulloblastoma-SLCs. Stem Cells International, 2016, 2016, 1-10.	2.5	8
256	Microarray expression studies on bone marrow of patients with Shwachman-Diamond syndrome in relation to deletion of the long arm of chromosome 20, other chromosome anomalies or normal karyotype. Molecular Cytogenetics, 2020, 13, 1.	0.9	8
257	Children and Fecal SARS-CoV-2 shedding: Just the tip of the Iceberg of Italian COVID-19 outbreak?. Digestive and Liver Disease, 2020, 52, 1219-1221.	0.9	8
258	Thioridazine requires calcium influx to induce MLL-AF6–rearranged AML cell death. Blood Advances, 2020, 4, 4417-4429.	5.2	8
259	Lessons from the COVID-19 Pandemic—Unique Opportunities for Unifying, Revamping and Reshaping Epidemic Preparedness of Europe's Public Health Systems. International Journal of Infectious Diseases, 2020, 101, 361-366.	3.3	8
260	The Pediatric Acute Leukemia Fusion Oncogene ETO2â€GLIS2 Increases Selfâ€Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cellsâ€Derived Model. HemaSphere, 2020, 4, e319.	2.7	8
261	Downregulation of miRâ€326 and its host gene βâ€arrestin1 induces proâ€survival activity of E2F1 and promotes medulloblastoma growth. Molecular Oncology, 2021, 15, 523-542.	4.6	8
262	CD19 expression in pediatric patients with relapsed/refractory Bâ€cell precursor acute lymphoblastic leukemia preâ€and postâ€treatment with blinatumomab. Pediatric Blood and Cancer, 2021, 68, e29323.	1.5	8
263	CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells. Blood, 2018, 132, 3491-3491.	1.4	8
264	Administration of BPX-501 Cells Following A \hat{I}^2 T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias. Blood, 2018, 132, 307-307.	1.4	8
265	Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a realâ€world setting: Results from the NEUF study. Pediatric Blood and Cancer, 2022, 69, e29562.	1.5	8
266	Rhabdomyosarcoma with Primary Osteolytic Lesions Simulating Non-Hodgkin's Lymphoma. Pediatric Hematology and Oncology, 1991, 8, 159-164.	0.8	7
267	Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO). Blood, 2019, 134, 1294-1294.	1.4	7
268	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2019, 134, 3873-3873.	1.4	7
269	Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7. Blood, 2012, 120, 1699-1699.	1.4	7
270	PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP). Blood, 2014, 124, 1450-1450.	1.4	7

#	Article	IF	CITATIONS
271	Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol. Leukemia and Lymphoma, 2017, 58, 999-1001.	1.3	6
272	Phenotypic and functional characterization of mesenchymal stromal cells isolated from pediatric patients with severe idiopathic nephrotic syndrome. Cytotherapy, 2018, 20, 322-334.	0.7	6
273	Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP). Blood Cancer Journal, 2018, 8, 115.	6.2	6
274	Phase I doseâ€escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Pediatric Blood and Cancer, 2019, 66, e27900.	1.5	6
275	Blinatumomab use in pediatric patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from an open-label, multicenter, expanded access study Journal of Clinical Oncology, 2017, 35, 10530-10530.	1.6	6
276	Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation. Oncotarget, 2016, 7, 82123-82138.	1.8	6
277	Response to comment on Multifunctional human CD56low CD16low NK cells are the prominent subset in bone marrow of both pediatric healthy donors and leukemic patients. Haematologica, 2015, 100, e332-3.	3.5	6
278	The long non-coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics. IScience, 2021, 24, 103350.	4.1	6
279	Refractory Cytopenia In Childhood (RCC) with Normal Karyotype Is Unlikely to Progress to Advanced MDS Under a Watch and Wait Strategy. Blood, 2010, 116, 4007-4007.	1.4	6
280	Human mesenchymal stromal cells primed with paclitaxel, apart from displaying anti-tumor activity, maintain their immune regulatory functions in vitro. Cytotherapy, 2014, 16, 868-870.	0.7	5
281	Cord blood transplantation in children with hemoglobinopathies. Expert Opinion on Orphan Drugs, 2015, 3, 1125-1136.	0.8	5
282	<i $>$ î $<$ /i>-Arrestin1/miR-326 Transcription Unit Is Epigenetically Regulated in Neural Stem Cells Where It Controls Stemness and Growth Arrest. Stem Cells International, 2017, 2017, 1-11.	2.5	5
283	Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. British Journal of Haematology, 2020, 188, e101-e105.	2.5	5
284	Glucocorticoids inhibit human hematopoietic stem cell differentiation toward a common ILC precursor. Journal of Allergy and Clinical Immunology, 2022, 149, 1772-1785.	2.9	5
285	Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. Pediatric Blood and Cancer, 2022, 69, e29557.	1.5	5
286	Characterization of <scp>KIR</scp> ⁺ <scp>NK</scp> cell subsets with a monoclonal antibody selectively recognizing <scp>KIR2DL1</scp> and blocking the specific interaction with <scp>HLA </scp> . Hla, 2022, , .	0.6	5
287	FGFR1 is a potential therapeutic target in neuroblastoma. Cancer Cell International, 2022, 22, 174.	4.1	5
288	Method using urokinase and an antibiotic to avoid device removal in central venous catheter-related infections. Medical and Pediatric Oncology, 2000, 35, 434-435.	1.0	4

#	Article	IF	CITATIONS
289	Whole Genome <scp>MBD</scp> â€seq reveals different CpG methylation patterns in Azacytidineâ€treated Juvenile Myelomonocytic Leukaemia (<scp>JMML</scp>) patients. British Journal of Haematology, 2018, 182, 909-912.	2.5	4
290	Targeting Hedgehog pathway in pediatric acute myeloid leukemia: challenges and opportunities. Expert Opinion on Therapeutic Targets, 2019, 23, 87-91.	3.4	4
291	QuantiFERONâ€₹B Gold can help clinicians in the diagnosis of haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2020, 191, e64-e67.	2.5	4
292	Immuneâ€based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies. HemaSphere, 2020, 4, e423.	2.7	4
293	Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning Techniques. Journal of Clinical Medicine, 2020, 9, 1670.	2.4	4
294	Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients — a 25â€year Italian experience. British Journal of Haematology, 2021, 195, 278-283.	2.5	4
295	A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors Journal of Clinical Oncology, 2019, 37, 10035-10035.	1.6	4
296	Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R) Tj ETQq0 () 0 t gBT /0	Overlock 10 Tf
297	Lack of splice factor and cohesin complex mutations in pediatric myelodysplastic syndrome. Haematologica, 2016, 101, e479-e481.	3.5	3
298	The EUREâ€CART project as a prototype model for CAR Tâ€eell immunotherapy in Europe. European Journal of Immunology, 2018, 48, 216-219.	2.9	3
299	Repurposing anthelmintic agents to eradicate resistant leukemia. Blood Cancer Journal, 2020, 10, 72.	6.2	3
300	Ethics in clinical autopsy. Journal of Clinical Pathology, 2021, 74, 339-343.	2.0	3
301	Identification of New Soluble Factors Correlated With the Development of Graft Failure After Haploidentical Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 613644.	4.8	3
302	Identification of a new <i><scp>HLAâ€B</scp>*44</i> allele, <i><scp>HLAâ€B</scp>*44:02:68</i> , by next generation sequencing. Hla, 2021, 98, 162-163.	0.6	3
303	NUP98 Fusion Proteins Are Recurrent Aberrancies in Childhood Acute Myeloid Leukemia: A Report from the AIEOP AML-2001-02 Study Group. Blood, 2014, 124, 1025-1025.	1.4	3
304	Rabbit anti-human T-lymphocyte globulin and hematopoietic transplantation. Oncotarget, 2017, 8, 96460-96461.	1.8	3
305	Successful of Chemo-Free Treatment with Dasatinib and Blinatumomab in a Pediatric EBF1-PDGFRÎ ² Positive Acute Lymphoblastic Leukemia. Blood, 2018, 132, 5213-5213.	1.4	3
306	Steroid-Refractory Acute Gvhd in Children: Retrospective Analysis of the AIEOP HSCT Registry. Blood, 2018, 132, 4578-4578.	1.4	3

#	Article	IF	CITATIONS
307	Identification of the novel <scp>HLAâ€B</scp> allele, <scp><i>HLAâ€B*44:532</i></scp> by nextâ€generation sequencing. Hla, 2022, 99, 210-211.	0.6	3
308	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS. Haematologica, 2022, 107, 759-764.	3.5	3
309	Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient. Bone Marrow Transplantation, 2022, 57, 1600-1603.	2.4	3
310	Juvenile chronic myelogenous leukemia: In vitro characterization before and after allogeneic bone marrow transplantation. Medical and Pediatric Oncology, 1995, 24, 166-170.	1.0	2
311	Possible roads to improve hemophagocytic lymphohistiocytosis outcome. Blood Advances, 2020, 4, 6127-6129.	5.2	2
312	Use of ruxolitinib to control graft-versus-host–like disease in Omenn syndrome and successfully bridging to HSCT. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2531-2533.e1.	3.8	2
313	The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study. Leukemia Research, 2021, 108, 106652.	0.8	2
314	Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. British Journal of Haematology, 2002, 116, 465-467.	2.5	2
315	Comparative Analysis of Alpha-Beta T-Cell and B-Cell Depleted (abTCD) HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) Versus Abtcd Haplo-HSCT with T-Cell Add-Back of Rivogenlecleucel Cell [Donor T Cells Transduced with the Inducible Caspase 9 (iC9) Gene Safety Switchl in Children with High-Risk Acute Leukemia (AL) in Remission, Blood, 2019, 134, 145-145.	1.4	2
316	Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO). Blood, 2020, 136, 24-25.	1.4	2
317	CRLF2 over-Expression Is a Poor Prognostic Marker in Children with High Risk T-Cell Acute Lymphoblastic Leukemia. Blood, 2014, 124, 1071-1071.	1.4	2
318	Comparison Between Related T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (TCD-Haplo) and Umbilical Cord Blood Transplantation (UCBT) in Pediatric Patients with Acute Leukemia, a Eurocord, PDWP-EBMT Study. Blood, 2014, 124, 1215-1215.	1.4	2
319	Outcome Of Unrelated Umbilical Cord Blood Transplantation For Children With Osteopetrosis: An Eurocord and Inborn Errors Working Party (IEWP)-EBMT Study. Blood, 2013, 122, 2100-2100.	1.4	2
320	Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent \hat{l}^2 -Thalassemia Treated at the Bambino Ges \tilde{A}^1 Children's Hospital, Rome, Italy. Blood, 2019, 134, 969-969.	1.4	2
321	MB-34CIRCULATING microRNAs IN GROUP 4 MEDULLOBLASTOMA PATIENTS. Neuro-Oncology, 2016, 18, iii104.3-iii104.	1.2	1
322	Preservation of Antigen-Specific Functions of $\hat{l}\pm\hat{l}^2$ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy. Frontiers in Immunology, 2017, 8, 332.	4.8	1
323	Alpha/Beta T-Cell and B-Cell Depletion HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is an Effective Treatment for Children/Young Adults with Acute Leukemia. Blood, 2018, 132, 2169-2169.	1.4	1
324	Impact of Minimal Residual Disease (MRD) Assessed before Transplantation on the Outcome of Children with Acute Myeloid Leukemia Given an Allograft: A Retrospective Study By the I-BFM Study Group. Blood, 2020, 136, 38-39.	1.4	1

#	Article	IF	CITATIONS
325	Impact of Minimal Residual Disease at Unrelated Cord Blood Transplantation In Children with Acute Lymphoblastic Leukemia In Remission: a Study on Behalf of Eurocord-EBMT and EBMT-PDWP. Blood, 2010, 116, 532-532.	1.4	1
326	FLT3-ITD As a Target for Minimal Residual Disease Monitoring in Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia. Blood, 2014, 124, 1073-1073.	1.4	1
327	Outcome of Early T-Cell Precursor Acute Lymphoblastic Leukemia in AIEOP Patients Treated with the AIEOP-BFM ALL 2000 Study. Blood, 2014, 124, 3780-3780.	1.4	1
328	A phase I/II study of eribulin mesilate (ERI) plus irinotecan (IRI) in children with refractory or recurrent solid tumors Journal of Clinical Oncology, 2020, 38, 10535-10535.	1.6	1
329	Single-agent dose-finding cohort of a phase 1/2 study of lenvatinib (LEN) in children and adolescents with refractory or relapsed solid tumors Journal of Clinical Oncology, 2017, 35, 10544-10544.	1.6	1
330	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). Blood, 2021, 138, 1235-1235.	1.4	1
331	Response of Patients with Transfusion-Dependent \hat{l}^2 -Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for \hat{l}^2 -Thalassemia) Gene Therapy Based on <i>HBB</i> Genotype and Disease Genetic Modifiers. Blood, 2020, 136, 1-3.	1.4	1
332	NK cell content does not seem to influence engraftment in exÂvivo TÂcell depleted haploidentical stem cell transplantation. Stem Cell Reports, 2022, 17, 443-445.	4.8	1
333	Case Report: Precision COVID-19 Immunization Strategy to Overcome Individual Fragility: A Case of Generalized Lipodystrophy Type 4. Frontiers in Immunology, 2022, 13, 869042.	4.8	1
334	HGG-46. Inter and Intra-tumor Heterogeneity of Pediatric-type Diffuse High-Grade Glioma Revealed by High-Dimensional Single-Cell Proteomics. Neuro-Oncology, 2022, 24, i71-i71.	1.2	1
335	Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group. Biomedicines, 2022, 10, 1530.	3.2	1
336	T Cell Immunotherapy for Immune Reconstitution and GVHD Prevention After Allogeneic Hematopoietic Stem Cell Transplantation. Current Stem Cell Reports, 2015, 1, 206-214.	1.6	0
337	TMOD-14. INNOVATIVE 3D MODEL FOR THE ESTABLISHMENT OF PRIMARY PAEDIATRIC LOW-GRADE GLIOMA (LGG) CULTURES: NEW PLATFORM FOR ADVANCED PRECLINICAL STUDIES OF INNOVATIVE AND IMMUNOTHERAPEUTIC APPROACHES. Neuro-Oncology, 2019, 21, ii123-ii124.	1.2	0
338	TMOD-05. GENOME-WIDE DNA METHYLATION PROFILE: A POWERFUL STRATEGY TO RECAPITULATE HETEROGENEITY OF PEDIATRIC BRAIN TUMORS IN PRIMARY CELL LINES. Neuro-Oncology, 2021, 23, i36-i36.	1.2	0
339	A Complex Karyotype but Not Monosomy 7 Is an Independent Prognostic Factor in Advanced Childhood MDS Blood, 2007, 110, 2452-2452.	1.4	0
340	BAG1 Overexpression Restrains the Anti-Apoptotic BCL2, MCL1 and HSP70 Proteins in Acute Myeloid Leukemia Blood, 2012, 120, 2492-2492.	1.4	0
341	Molecular Aberrations in 107 Children with Myelodysplastic Syndrome (MDS) Blood, 2012, 120, 2802-2802.	1.4	0
342	NOVEL Recurrent Genetic Aberrations in Pediatric AML: An AIEOP AML-2002 Study Group Blood, 2012, 120, 2494-2494.	1.4	0

#	Article	IF	Citations
343	Core Binding Factor Acute Myeloid Leukemia In Pediatric Patients Of The AIEOP AML 2002/01 Trial: Screening and Prognostic Impact Of cKIT Mutations. Blood, 2013, 122, 2655-2655.	1.4	0
344	Role of Allogeneic Hematopoietic Stem Cell Transplantation in t(4;11) Positive Acute Lymphoblastic Leukemia (ALL): A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Blood, 2014, 124, 1243-1243.	1.4	0
345	Intrabone Injection of T-Cell Depleted Peripheral Blood Stem Cells from HLA-Haploidentical Donors to Reduce the Risk of Graft Rejection in Children. Blood, 2014, 124, 1146-1146.	1.4	0
346	Response to High Dose Imatinib and Long-Term Outcome in Children and Adolescents with Previously Untreated Chronic Myeloid Leukemia in Chronic Phase. the Italian Experience. Blood, 2014, 124, 1812-1812.	1.4	О
347	Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSG). Blood, 2014, 124, 3670-3670.	1.4	0
348	Bone Marrow Immunophenotyping By Flow Cytometry in Refractory Cytopenia of Childhood. Blood, 2014, 124, 1916-1916.	1.4	0
349	Secondary Mutations of JAK3 and SETBP1 in Juvenile Myelomonocytic Leukemia and Their Propagating Capacity; A Report from the AIEOP Study Group. Blood, 2014, 124, 4625-4625.	1.4	0
350	Febuxostat Pharmacokinetic/Pharmacodynamic Bridging from Adults to Pediatrics for Effective Prophylaxis of Tumor Lysis Syndrome: From Florence to Floret Study. Blood, 2015, 126, 4868-4868.	1.4	0
351	Indications for Hematopoietic Stem Cell Transplantation in Children. , 2018, , 55-81.		0
352	Long-Term Outcome of Children with Acute Leukemia (AL) Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT). Blood, 2019, 134, 799-799.	1.4	0
353	MODL-23. DNA METHYLATION AND COPY NUMBER VARIATION PROFILE FOR CHARACTERIZATION OF PEDIATRIC BRAIN TUMOR PRIMARY CELL LINES. Neuro-Oncology, 2020, 22, iii415-iii415.	1.2	0
354	MBCL-18. ANALYSIS OF DNA METHYLATION PROFILES OF PEDIATRIC MEDULLOBLASTOMAS: EXPERIENCE AT THE BAMBINO GESÙ CHILDREN'S HOSPITAL. Neuro-Oncology, 2020, 22, iii391-iii392.	1,2	0
355	IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology, 2020, 22, iii362-iii362.	1,2	0
356	HGG-54. HISTOLOGICAL AND MOLECULAR CHARACTERIZATION OF HIGH-GRADE BRAIN TUMORS SECONDARY TO TOTAL BODY IRRADIATION FOR HEMATOLOGICAL MALIGNANCIES. Neuro-Oncology, 2020, 22, iii353-iii354.	1,2	0
357	Minimal Residual Disease and Outcome Characteristics in Infant KMT2A-Germline Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Blood, 2021, 138, 2383-2383.	1.4	0
358	Outcome of Children with Wiskott-Aldrich Syndrome (WAS) Given TCR Alpha-Beta/CD19 Depleted Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Haploidentical Relative. Blood, 2021, 138, 1775-1775.	1.4	0
359	Incidence and Therapeutic Implications of Germline <i>TP53</i> Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort. Blood, 2020, 136, 43-44.	1.4	0
360	Analysis of Hospitalization Events in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH) Treated with Emapalumab. Blood, 2020, 136, 24-24.	1.4	0

#	Article	IF	CITATIONS
361	Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis. Blood, 2020, 136, 31-32.	1.4	O
362	Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Analysis of a Multinational, Prospective, Observational Registry Study. Blood, 2020, 136, 32-33.	1.4	0
363	Outcome of Children with Different Non-Malignant Disorders Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT). Blood, 2020, 136, 2-4.	1.4	O
364	Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study. Blood, 2020, 136, 24-25.	1.4	0
365	Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH). Blood, 2020, 136, 14-15.	1.4	O
366	MEDB-46. ONC201 affects Group 3 Medulloblastoma growth by impairing cancer stem cells. Neuro-Oncology, 2022, 24, i116-i116.	1.2	0